Bora Pharmaceutical has announced a strategic alliance with Tanvex BioPharma, acquiring a 30.5% stake in the company, making it the largest shareholder. The deal involves Taifu issuing new ordinary shares in exchange for equity in Bora Pharmaceutical, which manages Bora’s large molecule CDMO (Contract Development and Manufacturing Organization) business.
This alliance aims to integrate resources, positioning Bora as a leading Taiwanese company with full-service capabilities in biologics, from cell line screening to final product filling. The partnership will enhance Bora’s presence in the U.S. market, particularly through Taifu’s established operations in San Diego, which focus on cancer treatments and antibody drugs.
The merger is set to be approved in upcoming shareholders’ meetings, with Bora’s CEO, Bobby Sheng, expected to become the new chairman of Tanvex BioPharma. This deal marks Bora’s third major strategic move in 2024, further solidifying its position as a global player in the biopharmaceutical industry.
